SCHEMBL5004887

SCHEMBL5004887

COc1cc(O)ccc1-n1c(C)cc(C(C)=O)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
MAPK1 P28482 2/20 0.49
HPGD P15428 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
NOTUM Q6P988 6/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
MYC P01106 2/20 0.42
PTPN1 P18031 1/20 0.42
MAOB P27338 2/20 0.41
CAPN1 P07384 1/20 0.41
PARP1 P09874 1/20 0.41
MAOA P21397 1/20 0.41
HTT P42858 2/20 0.41
NR4A1 P22736 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.40
HIF1A Q16665 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5004537 0.86 ALDH1A1 (0.49) ALDH1A1MAPK1HPGDTDP1NOTUM
SCHEMBL5004604 0.81 MAPK1 (0.56) ALDH1A1MAPK1HPGDMAPTLMNA
SCHEMBL5005526 0.81 NOTUM (0.50) ALDH1A1MAPK1HPGDTDP1NOTUM
Isopeonol SCHEMBL1376231 0.73 MAOB (0.57) ALDH1A1MAPK1HPGDTDP1MAPT
Isopeonol SCHEMBL29757918 0.73 MAOB (0.57) ALDH1A1MAPK1HPGDTDP1MAPT
Isopeonol SCHEMBL3713802 0.73 MAOB (0.57) ALDH1A1MAPK1HPGDTDP1MAPT
SCHEMBL563973 0.70 ALDH1A1 (0.56) ALDH1A1MAPK1HPGDTDP1MAPT
SCHEMBL8361031 0.70 CACNA2D1 (0.48) ALDH1A1HPGDMAPTMAOBHTT
SCHEMBL5004589 0.68 NOTUM (0.53) ALDH1A1MAPK1NOTUMMAPTLMNA
SCHEMBL5000999 0.67 NPC1 (0.60) ALDH1A1MAPK1HPGDMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465730-B2 Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds MERCK & CO. INC. (US) 2008-12-16 US disclosed
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds MERCK SHARP & DOHME CORP. 2006-07-13 US disclosed
EP-1539168-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO(3,4-D)PYRIDAZINE COMPOUNDS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2004006836-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS MERCK & CO., INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds GRIN2C, CACNA1C, CACNG4 ALDH1A1 1590/4885MAPK1 3323/4885HPGD 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.